Better Therapeutics, Inc. (BTTX): Price and Financial Metrics


Better Therapeutics, Inc. (BTTX): $1.37

0.06 (+4.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BTTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BTTX Stock Price Chart Interactive Chart >

Price chart for BTTX

BTTX Price/Volume Stats

Current price $1.37 52-week high $5.10
Prev. close $1.31 52-week low $0.91
Day low $1.32 Volume 9,579
Day high $1.44 Avg. volume 25,440
50-day MA $1.38 Dividend yield N/A
200-day MA $1.62 Market Cap 32.53M

Better Therapeutics, Inc. (BTTX) Company Bio


As of October 29, 2021, Mountain Crest Acquisition Corp. II was acquired by Better Therapeutics, Inc., in a reverse merger transaction. Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.


BTTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BTTX Latest Social Stream


Loading social stream, please wait...

View Full BTTX Social Stream

Latest BTTX News From Around the Web

Below are the latest news stories about BETTER THERAPEUTICS INC that investors may wish to consider to help them evaluate BTTX as an investment opportunity.

Better Therapeutics Posts Encouraging Data Establishing Proof-Of-Concept For Prescription Digital Therapy Platform

Full story available on Benzinga.com

Benzinga | December 8, 2022

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address t

Business Wire | December 8, 2022

Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that the compensation committee of Better Therapeutics’ board of directors approved the grant of a nonqualified stock option exercisable for 200,000 shares of Better Therapeutics’ common stock to Diane Gomez-Thinnes, Chief Commercial Officer, under the

Business Wire | December 2, 2022

Industries - Better Therapeutics versus Its Competitors Financial Review

Better Therapeutics is one of 33 public companies in the “Health services” industry, but how does it compare to its competitors? We will compare Better Therapeutics to related…

Business Mag | November 26, 2022

Better Therapeutics to Participate in BTIG Digital Health Forum

SAN FRANCISCO, November 15, 2022--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executive Officer, and Mark Berman, MD, Chief Medical Officer, will participate in a virtual fireside chat at the BTIG Digital Health Forum on Monday, November 21, 2022, at 2:00 p.m. ET / 11:00 a.m. PT. Better Therapeutics manag

Yahoo | November 15, 2022

Read More 'BTTX' Stories Here

BTTX Price Returns

1-mo 23.98%
3-mo -6.80%
6-mo -33.17%
1-year -64.51%
3-year N/A
5-year N/A
YTD 23.98%
2022 -76.24%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6925 seconds.